Multiple Myeloma

Elranatamab enhances MRD negativity in relapsed/refractory multiple myeloma post idecabtagene vicleucel, promising improved treatment outcomes.

Belantamab mafodotin with bortezomib shows promising survival benefits for lenalidomide-refractory multiple myeloma patients.

Intravenous immunoglobulin (IVIG) treatment significantly reduces infection rates in multiple myeloma patients receiving BCMA bispecific antibodies, showcasing its clinical benefits.

Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.

The 2025 International Myeloma Society Annual Meeting unveils crucial updates to IMWG guidelines, enhancing response assessment and treatment strategies for multiple myeloma.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

Subcutaneous bortezomib shows fewer adverse effects in multiple myeloma treatment compared with intravenous administration, enhancing patient outcomes.

For pharmacists, understanding the evolving therapeutic landscape is essential—not only to optimize drug selection and dosing but also to counsel patients on complex regimens, manage adverse effects, and monitor for treatment-related toxicities.

A patient, who formerly had previously been treated with CAR therapy for multiple myeloma, achieved remission for both multiple myeloma and lymphoma.

New research uncovers the complex tumor microenvironment in multiple myeloma, revealing unique plasma cell ecosystems that challenge existing treatment approaches.

SWIFT-seq revolutionizes multiple myeloma diagnosis, offering a noninvasive blood test that enhances monitoring and risk assessment for patients.

CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression free at 5 years without maintenance.

Discover the latest advancements in multiple myeloma treatment, including new therapies and FDA approvals that enhance patient outcomes and survival rates.

Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission.

Sanofi's SAR446523 receives orphan drug designation for relapsed/refractory multiple myeloma, enhancing treatment options and patient outcomes.

Sundar Jagannath, MD, discusses how prophylactic tocilizumab reduced cytokine release syndrome incidence and severity with talquetamab in relapsed or refractory (R/R) multiple myeloma.

Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, explore how the removal of risk evaluation and management strategies (REMS) for chimeric antigen receptor (CAR) T-cell (CAR T) therapies can improve health equity, expand access in community settings, and elevate the pharmacist’s role in care coordination.

The advisory committee cited concerns around ocular toxicity and overall tolerability, raising serious questions about the drug's benefit-risk profile ahead of its scheduled Prescription Drug User Fee Act action date on July 23, 2025.

The National Comprehensive Cancer Network (NCCN) has released multiple myeloma guidelines version 2.2026 to include linvoseltamab as a preferred treatment for heavily pretreated patients, highlighting its intravenous formulation, dosing options, and streamlined Risk Evaluation and Mitigation Strategy program.

The data showed patients with relapsed or refractory multiple myeloma achieved a 73% overall response rate.

Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, discuss the ramifications of the FDA's removal of REMS requirements for approved chimeric antigen receptor (CAR) T-cell (CAR T) therapies.

The long-term outcomes from the CARTITUDE-1 trial in multiple myeloma and durable complete response data from the STARGLO trial in diffuse large B-cell lymphoma can be significant for these disease states.

New data reveal isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.

The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma.

CARTITUDE-1 trial reveals cilta-cel's potential in achieving long-term remission for relapsed/refractory multiple myeloma, sparking discussions on curative possibilities.